Review of the status of neoadjuvant therapy in HER2-positive breast cancer.

Dowling, Gavin P; Keelan, Stephen; Toomey, Sinead; Daly, Gordon R; Hennessy, Bryan T; Hill, Arnold D K

Dowling, Gavin P; Keelan, Stephen; Toomey, Sinead; Daly, Gordon R; Hennessy, Bryan T; Hill, Arnold D K.

Afiliação

Dowling GP; Medical Oncology Lab, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Keelan S; The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Toomey S; The Department of Surgery, Beaumont Hospital, Dublin, Ireland.
Daly GR; The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Hennessy BT; The Department of Surgery, Beaumont Hospital, Dublin, Ireland.
Hill ADK; Medical Oncology Lab, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Front Oncol ; 13: 1066007, 2023.

Article em En | MEDLINE | ID: mdl-36793602

Palavras-chave

HER2 (human epidermal growth factor 2); antibody-drug-conjugates; biomarker; breast cancer; neoadjuvant therapy; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irlanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google